In this context, recent research endeavors have reformulated BTZ using liposomal techniques, including surface conjugation or encapsulation [10], and these liposomal formulations were evaluated in various cancer models, such as colon cancer, melanoma [26], or neuroblastoma [27], to determine the broader therapeutic potential of L-BTZ. The gene discussed is CASC3; the disease is neuroblastoma.